Vector Bioscience

Vector Bioscience is a drug delivery company based in Cambridge, UK, that specializes in the development of a machine-learning empowered nanoparticle platform. Utilizing Metal-Organic Frameworks (MOFs), the company's "Nanoshuttle" technology enables the precise, controlled, and targeted release of various therapeutic cargoes, including small molecules, biologics, and RNA-based drugs. The platform is designed to be cargo-agnostic and compatible with multiple administration routes, aiming to improve the efficacy and safety of oncology treatments by minimizing off-target effects. Vector Bioscience is currently advancing its preclinical pipeline with a focus on hard-to-treat cancers such as pancreatic cancer, lung cancer, and mesothelioma.